ClinicalTrials.gg
CompletedNCT05583526TranquilloUpdated Feb 27, 2026

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A Phase 3 interventional study of Ritlecitinib and Placebo in Stable Nonsegmental Vitiligo and Active Nonsegmental Vitiligo, sponsored by Pfizer. Completed at 115 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
3rd of 68
607 · median 37
Started
2022
with 4 others
Phase 3
12 of 80
1 open now
Registered
55th of 80
by date
Lead sponsor
4 of 80
Pfizer

Among the 80 studies in Vitiligo with a site in United States, this one is the 3rd largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 3, and was the 55th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Read the detailed description

Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo (both active and stable vitiligo).

03

Conditions studied

  • Stable Nonsegmental Vitiligo
  • Active Nonsegmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥18 years of age at Screening. Adolescents (12 to \<18 years of age) are also eligible for this study, but only if approved by the local IRB/EC and regulatory health authority. Where these approvals have not been granted, only participants ≥18 years of age will be enrolled.

    Disease Characteristics:

  2. Eligible participants must have at both Screening and Baseline:

    • A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
    • BSA involvement 4%-60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet; and
    • BSA ≥0.5% involvement on the face (face is defined as including the area on the forehead to the original hairline, on the cheek vertically to the jawline, and laterally from the corner of the mouth to the tragus. The face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
    • F-VASI ≥0.5 \& T-VASI ≥3; and
    • Either active or stable disease nonsegmental vitiligo at both Screening and Baseline visits. All participants who do not have the features of active vitiligo (defined below) are required to have stable disease.

    Active vitiligo is defined as:

    • Participants will be classified as having active vitiligo based on the presence of at least one active lesion at baseline defined as one of the following:
    • New/extending lesion(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record):
    • Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
    • Trichrome lesion(s);Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
    • Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.

    Stable vitiligo is defined as an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) are required to have stable disease.

    Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.

    Other Inclusion Criteria:

  3. If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
  4. Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Any psychiatric condition including recent or active suicidal ideation or behavior that meets any of the following criteria:

    • Suicidal ideation associated with actual intent and a method or plan in the past year: "Yes" answers on items 4 or 5 of the C-SSRS administered at the screening visit.
    • Previous history of suicidal behaviors in the past 5 years: "Yes" answer (for events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS.
    • For adults, any lifetime history of serious suicidal behavior or recurrent suicidal behavior. For adolescents, any previous lifetime history of suicidal behavior.
  2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:

    • Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criterion #2 (including, but not limited to, segmental vitiligo and mixed vitiligo).
    • Currently have active forms of other disorders of pigmentation (including but not limited to Vogt-Koyanagi-Harada disease, -induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma (all types, including mixed), and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
    • Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or Baseline Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
    • Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions OR leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
    • Have a superficial skin infections within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
  3. General Infection History:

    • Having a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged by the investigator within 6 months prior to Day 1.
    • Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
    • Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium TB
  4. Specific Viral Infection History:

    • History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
    • Infected with or viruses: all participants will undergo screening for hepatitis B and C for eligibility.
    • Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
    • Have a known immunodeficiency disorder (including positive serology for at screening) or a first-degree relative with a hereditary immunodeficiency.
  5. Medical Conditions, Other:

    • Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
    • History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/ to any component (including ) of the study intervention.
    • Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating or progressive.
    • Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
    • Abnormal findings on the Screening chest imaging (eg, chest x-ray) that may increase the risk associated with study participation including, but not limited to, presence of active TB, general infections, cardiomyopathy, or malignancy. Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
    • Long Syndrome, a family history of Long QT Syndrome, or a history of TdP.
    • Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
    • Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.

    Prior/Concomitant Therapy:

  6. Have received any of the prohibited treatment regimens specified.

    Prior/Concurrent Clinical Study Experience:

  7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.

    Diagnostic Assessments:

  8. Any of the following abnormalities in laboratory values at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:

    • Renal impairment
    • Hepatic dysfunction
  9. Screening standard 12-lead that demonstrates clinically relevant abnormalities

    Other Exclusion Criteria:

  10. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
  11. Adolescent participants 12 to \<18 years of age without one of the following:

    • Documented evidence from a health professional of having received varicella vaccination (2 doses); or
    • Evidence of prior exposure to VZV based on serological testing (ie, a positive VZV IgG Ab result) at Screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
607 participants (actual)

Study arms

  • Experimental
    Ritlecitinib 50 mg

    Ritlecitinib 50 mg QD (ritilecitinib 50 mg QD arm; approximately 400 participants)

    Drug: Ritlecitinib

  • Placebo comparator
    Placebo

    Placebo (placebo arm; approximately 200 participants)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: Week 52

  2. Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)

    Time frame: Week 52

  3. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities

    Safety and tolerability of ritlecitinib in participants with nonsegmental vitiligo

    Time frame: Baseline through Week 52

Secondary outcomes

  1. US-Only: Response based on F-VASI75 at 24 and 36 weeks

    Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline

    Time frame: Weeks 24 and 36

  2. US-Only: Response based on T-VASI50 at 24 and 36 weeks

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: Weeks 24 and 36

  3. US-Only: Response based on T-VASI75 at 52 weeks

    Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

    Time frame: Week 52

  4. US-Only: Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks

    Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 24, 36, and 52

  5. US-Only: Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks

    Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 24, 36, and 52

  6. US-Only: Patient Global Impression of Severity-Face (PGIS-F)

    Proportion of responders based on PGIS-F at 52 weeks

    Time frame: Week 52

  7. US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)

    Proportion of responders based on PGIS-V at 52 weeks

    Time frame: Week 52

  8. Global (Other than US): Response based on F-VASI75 at 24 and 36 weeks

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)

    Time frame: Weeks 24 and 36

  9. Global (Other Than US): Response based on T-VASI50 at 24, 36, and 52 weeks

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: Weeks 24, 36, and 52

  10. Global (Other than US): Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks

    Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 24, 36, and 52

  11. Global (Other than US): Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks

    Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 24, 36, and 52

  12. Global (Other than US): Patient Global Impression of Severity-Face (PGIS-F)

    Proportion of responders based on PGIS-F at 24, 36, and 52 weeks

    Time frame: Weeks 24, 36, and 52

  13. Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)

    Proportion of responders based on PGIS-V at 24, 36, and 52 weeks

    Time frame: Weeks 24, 36, and 52

  14. All Countries: Proportion of participants achieving disease stabilization

    The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD compared to placebo

    Time frame: Baseline through week 52

  15. Response based on T-VASI50

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 48

  16. Response based on F-VASI75

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 48

  17. Response based on T-VASI75

    Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 24, week 36, week 48

  18. Proportion of participants with sustained improvement in T-VASI

    Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52

    Time frame: Week 36 through week 52

  19. Proportion of participants with sustained improvement in F-VASI

    Defined as maintenance of ≥F-VASI75 from Week 36 to 52

    Time frame: Week 36 through week 52

  20. All Countries: Time to rescue medication

    Comparing time to rescue medication curves and difference in probabilities of using rescue medication

    Time frame: Baseline through week 52

  21. Percentage change from baseline in F-VASI

    Median % CFB in F-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Baseline through week 52

  22. Percentage change from baseline in T-VASI

    Median % CFB in T-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo

    Time frame: Baseline through week 52

  23. Response based on T-VASI90

    Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 52

  24. Response based on T-VASI100

    Proportion of participants achieving T-VASI100 (defined as at least 100% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 52

  25. Response based on F-VASI50

    Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline).

    Time frame: Baseline through week 52

  26. Response based on F-VASI90

    Proportion of participants achieving F-VASI90 (defined as at least 50% improvement in F-VASI from Baseline).

    Time frame: Baseline through week 52

  27. Response based on F-VASI100

    Proportion of participants achieving F-VASI100 (defined as at least 100% improvement in F-VASI from Baseline).

    Time frame: Baseline through week 52

  28. Patient Global Impression of Severity-Face (PGIS-F)

    Proportion of responders based on PGIS-F at 24 and 26 weeks

    Time frame: Weeks 24 and 36

  29. Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)

    Proportion of responders based on PGIS-V at 24 and 36 weeks

    Time frame: Weeks 24 and 36

  30. Patient Global Impression of Change-Face (PGIC-F)

    To assess the effect of ritlecitinib compared to placebo on the PGIC-F at 24, 36, and 52 weeks

    Time frame: Weeks 24, 36, and 52

  31. Patient Global Impression of Change- Overall Vitiligo (PGIC-V)

    To assess the effect of ritlecitinib compared to placebo on the PGIC-V at 24, 36, and 52 weeks

    Time frame: Weeks 24, 36, and 52

  32. Change from baseline in Dermatology Life Quality Index (DLQI) or Children Dermatology Life Quality Index (CDLQI)

    To evaluate the change from baseline in DLQI or CDLQI at week 52

    Time frame: Week 52

  33. Change from baseline in the Hospital Anxiety and Depression Scale (HADS)

    To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52

    Time frame: Week 52

  34. The proportion of patients achieving absence of depression on HADS depression subscale

    Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression)

    Time frame: Week 52

  35. The proportion of patients achieving absence of anxiety on HADS anxiety subscale

    Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety)

    Time frame: Week 52

07

Study locations

115 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham Faculty Office Towers (Regulatory
    Birmingham, Alabama 35294, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Wallace Medical Group, Inc
    Los Angeles, California 90056, United States
  • Audiology
    Washington D.C., District of Columbia 20007, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Center for Dermatology and Dermatologic Surgery
    Washington D.C., District of Columbia 20037, United States
  • Encore Medical Research of Boynton Beach
    Boynton Beach, Florida 33436, United States
  • Skin Care Research
    Hollywood, Florida 33021, United States
  • Clever Medical Research
    Miami, Florida 33126, United States
  • Ziaderm Research LLC
    North Miami Beach, Florida 33162, United States
  • Olympian Clinical Research
    St. Petersburg, Florida 33709, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Advanced Medical Research, PC.
    Sandy Springs, Georgia 30328, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Velocity Clinical Research at The Dermatology Clinic, Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • The NeuroMedical Center (XRay)
    Baton Rouge, Louisiana 70810, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Prairieville Family Hospital (XRay)
    Prairieville, Louisiana 70769, United States
  • Visage Dermatology and Aesthetic Center
    Bowie, Maryland 20716, United States
  • Lawrence J Green, MD LLC
    Rockville, Maryland 20850, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Hamzavi Dermatology - Canton
    Canton, Michigan 48187, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87102, United States
  • SUNY Downstate Health Sciences University
    Brooklyn, New York 11203, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27516, United States
  • Clinical & Translational Research Center (CTRC)
    Chapel Hill, North Carolina 27599, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28411, United States
  • Accellacare
    Wilmington, North Carolina 28411, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28411, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Remington Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
  • Alpesh D. Desai, DO PLLC - Research
    Houston, Texas 77008, United States
  • Austin Institute for Clinical Research
    Houston, Texas 77056, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • The Skin Hospital
    Darlinghurst, New South Wales 2010, Australia
  • North Eastern Health Specialists
    Campbelltown, South Australia 5074, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Dr Rodney Sinclair Pty Ltd
    East Melbourne, Victoria 3002, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • MC "Asklepiy" OOD
    Dupnitsa, 2600, Bulgaria
  • DCC Aleksandrovska EOOD
    Sofia, 1431, Bulgaria
  • UMHAT "Prof. dr. Stoyan Kirkovich" AD
    Stara Zagora, 6000, Bulgaria
  • Dermatology Research Institute
    Calgary, Alberta T2J 7E1, Canada
  • CaRe Clinic
    Red Deer, Alberta T4P 1K4, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • DermEdge Research
    Mississauga, Ontario L4Y 4C5, Canada
  • North York Research Inc
    Toronto, Ontario M2N3A6, Canada
  • Whitby Health Centre Dermatology trials
    Whitby, Ontario L1P 0p9, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Québec, G1V 4X7, Canada
  • Centre de Recherche Saint-Louis inc.
    Québec, G1W 4R4, Canada
  • Fujian Medical University Affiliated First Hospital
    Fuzhou, Fujian 350005, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • The First Hospital of Wuhan
    Wuhan, Hubei 430022, China
  • The First Hospital of China Medical University/Dermatology and STD Department
    Shenyang, Liaoning 110001, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Zhejiang Provincial People's Hospital/Dermatology Department
    Hangzhou, Zhejiang 310014, China
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310016, China
  • The first Affiliated hospital of Wenzhou medical University
    Wenzhou, Zhejiang 325000, China
  • Praxis Leitz und Kollegen
    Stuttgart, Baden-Wurttemberg 70178, Germany
  • Universitaetsklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, Lower Saxony 48455, Germany
  • Universitätsklinikum Münster
    Münster, North Rhine-Westphalia 48149, Germany
  • Istituto Clinico Humanitas, IRCCS
    Rozzano, Milano 20089, Italy
  • Istituti Fisioterapici Ospitalieri (IFO)
    Roma, RM 00144, Italy
  • Policlinico S. Orsola- Malpighi
    Bologna, 40138, Italy
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Dermatology and Ophthalmology Kume Clinic
    Sakai, Osaka 593-8324, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Sugamo Kobayashi Derma Clinic
    Toshima-Ku, Tokyo 170-0002, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu, Yamanashi 400-8506, Japan
  • Nippon Medical School Hospital
    Tokyo, 113-8603, Japan
  • Hospital Infantil de Mexico Federico Gomez
    Mexico City, Mexico City 06720, Mexico
  • Centro de Dermatologia de Monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Sociedad de Metabolismo y Corazon S.C.
    Veracruz, 91900, Mexico
  • Sociedad de Metabolismo Y Corazon Sc
    Veracruz, 91900, Mexico
  • Arké SMO S.A de C.V
    Veracruz, 91910, Mexico
  • DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.
    Osielsko, Kuyavian-Pomeranian Voivodeship 86-031, Poland
  • Royalderm Agnieszka Nawrocka
    Warsaw, Masovian Voivodeship 02-962, Poland
  • Twoja Przychodnia SCM
    Szczecin, West Pomeranian Voivodeship 71-500, Poland
  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    Lodz, Łódź Voivodeship 90-436, Poland
  • Dermedic Jacek Zdybski
    Ostrowiec Witokrzyski, Świętokrzyskie Voivodeship 27-400, Poland
  • Phoenix Pharma
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Clinresco Centres
    Kempton Park, Gauteng 1619, South Africa
  • Botho Ke Bontle Health Services
    Pretoria, Gauteng 0184, South Africa

Showing the first 100 of 115 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lukic T, Ghosh P, Napatalung L, Wang C, Kurosky SK, Hamzavi I, Sinclair R, Xiang L, Steil K, Rosmarin D, Parsad D, Ezzedine K, Adiri R. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. Dermatol Ther (Heidelb). 2026 Jul;16(7):3709-3727. doi: 10.1007/s13555-026-01724-y. Epub 2026 May 22. PubMed 42171987 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Feb 2026, 38 months.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2022
First posted
Oct 17, 2022
StartActual
Dec 1, 2022
Primary completionActual
Feb 5, 2026
CompletionActual
Feb 5, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05583526
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Dec 1, 2022
Primary completion
Feb 5, 2026
Completion
Feb 5, 2026
Last update
Feb 27, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion